These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 22718077)

  • 1. Pharmacotherapy for attention-deficit/hyperactivity disorder: from cells to circuits.
    Minzenberg MJ
    Neurotherapeutics; 2012 Jul; 9(3):610-21. PubMed ID: 22718077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Catecholamine dysfunction in attention-deficit/hyperactivity disorder: an update.
    Prince J
    J Clin Psychopharmacol; 2008 Jun; 28(3 Suppl 2):S39-45. PubMed ID: 18480676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder.
    Del Campo N; Chamberlain SR; Sahakian BJ; Robbins TW
    Biol Psychiatry; 2011 Jun; 69(12):e145-57. PubMed ID: 21550021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Translational approaches to frontostriatal dysfunction in attention-deficit/hyperactivity disorder using a computerized neuropsychological battery.
    Chamberlain SR; Robbins TW; Winder-Rhodes S; Müller U; Sahakian BJ; Blackwell AD; Barnett JH
    Biol Psychiatry; 2011 Jun; 69(12):1192-203. PubMed ID: 21047621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain abnormalities in attention-deficit hyperactivity disorder: a review.
    Rubia K; Alegría AA; Brinson H
    Rev Neurol; 2014 Feb; 58 Suppl 1():S3-16. PubMed ID: 25252664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MR imaging of the effects of methylphenidate on brain structure and function in attention-deficit/hyperactivity disorder.
    Schweren LJ; de Zeeuw P; Durston S
    Eur Neuropsychopharmacol; 2013 Oct; 23(10):1151-64. PubMed ID: 23165220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacotherapy of attention deficit hyperactivity disorder.
    Spencer T; Biederman J; Wilens T
    Child Adolesc Psychiatr Clin N Am; 2000 Jan; 9(1):77-97. PubMed ID: 10674191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neurobiology of attention deficit/hyperactivity disorder].
    Purper-Ouakil D; Lepagnol-Bestel AM; Grosbellet E; Gorwood P; Simonneau M
    Med Sci (Paris); 2010 May; 26(5):487-96. PubMed ID: 20510147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults.
    Wigal SB
    CNS Drugs; 2009; 23 Suppl 1():21-31. PubMed ID: 19621975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The dopamine transporter and attention-deficit/hyperactivity disorder.
    Madras BK; Miller GM; Fischman AJ
    Biol Psychiatry; 2005 Jun; 57(11):1397-409. PubMed ID: 15950014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the dopamine system in the treatment of attention-deficit/hyperactivity disorder.
    Staller JA; Faraone SV
    Expert Rev Neurother; 2007 Apr; 7(4):351-62. PubMed ID: 17425490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in structural and functional brain imaging studies of attention-deficit/hyperactivity disorder.
    Kelly AM; Margulies DS; Castellanos FX
    Curr Psychiatry Rep; 2007 Oct; 9(5):401-7. PubMed ID: 17915080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attention-deficit/hyperactivity disorder.
    Shaywitz BA; Fletcher JM; Shaywitz SE
    Adv Pediatr; 1997; 44():331-67. PubMed ID: 9265975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What are the cognitive effects of stimulant medications? Emphasis on adults with attention-deficit/hyperactivity disorder (ADHD).
    Advokat C
    Neurosci Biobehav Rev; 2010 Jul; 34(8):1256-66. PubMed ID: 20381522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ADHD: current and future therapeutics.
    Heal DJ; Smith SL; Findling RL
    Curr Top Behav Neurosci; 2012; 9():361-90. PubMed ID: 21487953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of methylphenidate treatment outcome in adults with attention-deficit/hyperactivity disorder (ADHD).
    Retz W; Retz-Junginger P
    Eur Arch Psychiatry Clin Neurosci; 2014 Nov; 264 Suppl 1():S35-43. PubMed ID: 25231833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A selective dopamine reuptake inhibitor improves prefrontal cortex-dependent cognitive function: potential relevance to attention deficit hyperactivity disorder.
    Schmeichel BE; Zemlan FP; Berridge CW
    Neuropharmacology; 2013 Jan; 64(1):321-8. PubMed ID: 22796428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel multidomain computerized cognitive assessment for attention-deficit hyperactivity disorder: evidence for widespread and circumscribed cognitive deficits.
    Leitner Y; Doniger GM; Barak R; Simon ES; Hausdorff JM
    J Child Neurol; 2007 Mar; 22(3):264-76. PubMed ID: 17621495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathophysiology of NSS in ADHD.
    Pasini A; D'agati E
    World J Biol Psychiatry; 2009; 10(4 Pt 2):495-502. PubMed ID: 19337883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Substance abuse in patients with attention-deficit hyperactivity disorder : therapeutic implications.
    Schubiner H
    CNS Drugs; 2005; 19(8):643-55. PubMed ID: 16097847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.